270: Your guide to Wegovys blockbuster heart study
In the wake of a massively important clinical trial of Novo Nordisk\u2019s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don\u2019t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.